D'Orazio & Associates
NGEN icon

D'Orazio & Associates’s NervGen Pharma NGEN Stock Holding History

D'Orazio & Associates’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Hold
10,000
– – ﹤0.01% 321
2026
Q1 		$37.7K Buy
+10,000
New +$43.3K ﹤0.01% 298

Other funds holding NGEN

Empery Asset Management
Empery Asset Management New York $86.5M AUM
Rock Springs Capital Management
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DAFNA Capital Management
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Ghisallo Capital Management
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LMR Partners
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

D'Orazio & Associates's NGEN Position: Q2 2026 in Review

D'Orazio & Associates held its NervGen Pharma (NGEN) position steady in Q2 2026 at 10,000 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #321.

D'Orazio & Associates first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $37.7K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • D'Orazio & Associates held 10,000 shares of NervGen Pharma worth $20.6K as of Q2 2026.
  • D'Orazio & Associates left its NervGen Pharma share count unchanged in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of D'Orazio & Associates's portfolio in Q2 2026, its #321 holding.
  • D'Orazio & Associates first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • D'Orazio & Associates's NervGen Pharma position peaked at $37.7K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.